Thrombosis. Other venous embolism and thrombosis
Conditions
Interventions
Intervention group: children with CVC-VTE that would receive 5 days of Enoxaparin and then 30 days of Rivaroxaban..
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
2 Years to 18 Years
Inclusion criteria
Inclusion criteria: Age 2-18 years old CVC-VTE diagnosed by US Doppler Five days received enoxaparin or heparin
Exclusion criteria
Exclusion criteria: Active bleeding History of anaphylaxis to rivaroxaban Usage of other anticoagulant drugs including ASA, platelet inhibitors, NSAID, Fibrinolytic, SSRI and SNRI Acutely ill patients with increased risk of bleeding including bronchiectasis, pulmonary cavitation, pulmonary hemorrhage, active cancer, recent HSCT in last 3 months, active GI ulcer or recent GI bleeding in the last 3 months, Liver disease with coagulopathy Patients needing spinal anesthesia or LP Creatinine clearance lower than 30 ml/min Platelet count lower than 75 X 109 Dialysis catheter or artificial heart leaflet Unstable hemodynamic
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrence of thrombosis. Timepoint: Efficacy of Rivaroxaban is evaluated by Doppler ultrasound conducted 30 days after drug administration. Method of measurement: Follow-up ultrasound. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAzadeh Kiumarsi
Tehran University of Medical Sciences
Outcome results
None listed